Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

NCT02790632 is registered in ClinicalTrials.gov with Edge Therapeutics Inc as lead sponsor.

NCT NCT02790632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02790632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
Lead sponsor
Edge Therapeutics Inc
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2016
Completion date
June 30, 2018
Enrollment
374 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

subarachnoid hemorrhage, aneurysmal